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AbstrAct
Objective To compare the effectiveness of 
corticosteroid injections to local anaesthetic injections 
in the management of rotator cuff-related shoulder pain 
(RCRSP).
Design Systematic review with best evidence synthesis.
Data sources The Cochrane, PubMed, CINAHL Plus, 
PEDro and EMBASE electronic databases were searched 
(inception until 8 June 2017). Reference lists of included 
articles were also hand searched.
Eligibility criteria Two reviewers independently 
evaluated eligibility. Randomised controlled trials (RCTs) 
were included if they compared subacromial injections of 
corticosteroid with anaesthetic injections. Two reviewers 
independently extracted data regarding short-term, 
midterm and long-term outcomes for pain, self-reported 
function, range of motion and patient-perceived 
improvement.
results Thirteen RCTs (n=1013) were included. Four 
trials (n=475) were judged as being at low risk of bias. 
Three studies of low risk of bias favoured the use of 
corticosteroid over anaesthetic-only injections in the 
short term (up to 8 weeks). There was strong evidence 
of no significant difference between injection types in 
midterm outcomes (12–26 weeks). There was limited 
evidence of no significant difference between injection 
types in long-term outcomes.
conclusion Corticosteroid injections may have a 
short-term benefit (up to 8 weeks) over local anaesthetic 
injections alone in the management of RCRSP. Beyond 
8 weeks, there was no evidence to suggest a benefit of 
corticosteroid over local anaesthetic injections.
trial registration number PROSPERO 
CRD42016033161.
bAckgrOunD 
Shoulder pain is a common musculoskeletal 
disorder with prevalence estimates ranging from 
6.9% to 26.0% for point prevalence, annual prev-
alence of 4.7%–46.7% and lifetime prevalence of 
6.7%–66.7%.1 Prevalence increases with age,2 and 
shoulder pain is frequently associated with long-
term disability.3–5 Injection therapy is a common 
intervention for musculoskeletal shoulder pain 
and is administered in primary and secondary 
care. In the UK, general practitioners administer 
corticosteroid (CS) injections to approximately 
1 in 10 people presenting with shoulder pain in 
primary care.3 Injection therapy for shoulder pain 
is also performed by physiotherapists, orthopaedic 
surgeons, rheumatologists, radiologists, sports and 
exercise medicine doctors and others in primary 
and secondary care, as well as in private settings. 
However, the definitive number of people receiving 
CS injections for musculoskeletal shoulder condi-
tions remains unknown. 
Rotator cuff-related shoulder pain (RCRSP)6 is 
an overarching clinical term and includes a number 
of other conditions: subacromial impingement 
syndrome,7 subacromial pain syndrome8 and rotator 
cuff tendinopathy.9 10 In addition to local tissue 
pathology, persistent pain associated with RCRSP 
may be related to altered processing and output of 
the central nervous system.11 12 Education, advice 
and exercise are the most common treatments for 
RCRSP6 and have comparable results to surgery.6 13 
Another very common treatment for this condition 
is injection therapy, which typically involves injec-
tions of CS in isolation, or more commonly, mixed 
with anaesthetic14 into the subacromial space.15 
For patients with RCRSP, CS or CS and anaesthetic 
preparations are often administered for treatment,3 
and anaesthetic injections alone are used for diag-
nosis, in a procedure known as the Neer impinge-
ment test.7
Although CS injections for RCRSP are common, 
the definitive mechanism of action is uncertain, 
with suggestions that they may have an anti-in-
flammatory role,16 reduce tenocyte numbers17 
and inhibit nociceptor activity.18 There is also 
uncertainty regarding clinical effectiveness with 
previous reviews suggesting their benefit maybe 
unclear,19 20 short lived,21–23 no greater than 
non-steroidal anti-inflammatories21 22 or beneficial 
for up to 9 months.24 In addition, there is emerging 
evidence linking the use of CS injections with nega-
tive effects on rotator cuff tissue.25–27 Due to these 
risks, anaesthetic-only injections (although not 
devoid of risk) might, when deemed appropriate, 
be considered a reasonable alternative to CS in 
the management of RCRSP.6 A recently published 
meta-analysis assessed short-term outcomes and 
concluded that CS injections provide, at best, a 
minimal transient pain reduction in a small number 
of patients with rotator cuff tendinosis.23
No previous review has directly compared 
CS alone, or CS and anaesthetic injections, with 
local anaesthetic-alone injections in the treatment 
of RCRSP. A comparison of this nature is relevant 
for a number of reasons, including the common use 
of injection therapy in the management of RCRSP,3 
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as well as: (1) the potential comparable clinical effectiveness of 
these medicines14 and (2) the potential deleterious effect of CS 
on tendon tissue.26
To inform the shared decision-making process, those seeking 
and providing treatment for RCRSP would be better informed 
with more knowledge on injection therapy, especially comparing 
the most commonly performed procedures (CS alone or CS and 
anaesthetic injections, with local anaesthetic-alone injections) in 
the management of RCRSP. Therefore, the aim of this review was 
to compare these pharmacological preparations in the manage-
ment of RCRSP for clinical effectiveness (symptoms, range of 
movement and function) in the short term, medium term and 
long term.
MEthODs
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) and Cochrane collaboration guide-
lines were followed.28–30 PROSPERO registration number: 
CRD42016033161.
Population
Inclusion criteria: studies with adult participants diagnosed with 
RCRSP were included.6 Exclusion criteria: participants with 
non-RCRSP shoulder conditions such as shoulder dislocation 
or instability, fractures, rheumatological conditions or frozen 
shoulder. Also, people who had undergone previous surgery, as 
well as those with confirmed full thickness rotator cuff tears.
Intervention/control
Inclusion criteria: randomised clinical trials. Studies were 
included if they compared groups receiving single or repeated: 
subacromial injections of CS with or without local anaesthetic 
versus local anaesthetic injection without CS. Concurrent 
prescription of exercise therapy, as well as prescription of pain 
relieving medications, such as analgesics and non-steroidal 
anti-inflammatory drugs (NSAIDs), was permitted inclusions, as 
this reflects common clinical management of RCRSP.6 31
Exclusion criteria: in the treatment of RCRSP, the subacromial 
space is the most common target for injections, and investiga-
tions of injection therapy that did not solely target this region32 33 
were excluded. Other injection procedures, such as barbotage, 
were also excluded.
Outcome
Outcome measures included shoulder pain, self-reported func-
tion, range of motion and patient-perceived improvement. 
Follow-up time postintervention was defined as short term (less 
than 3 months), midterm (3–12 months) and long term (a year 
or longer).34
Data sources
The Cochrane Library, PubMed, EMBASE, PEDro and ‘CINAHL 
plus’ databases were searched from inception to 8 June 2017 by 
two independent reviewers (TC and MM). No language, date 
or publication restrictions were applied. Search terms included 
‘shoulder’, ‘impingement’, ‘subacromial’, ‘injections’, ‘cortico-
steroid’ and ‘local anaesthetic’. These terms were linked broadly 
to the population, intervention, comparators and outcome 
elements for the review question (table 1).
The reference lists of retrieved articles, including previous 
systematic reviews, were assessed for additional study titles and 
relevant publications, including articles not identified in the 
search, personal communications, books and book chapters. 
study selection
Studies that were not randomised controlled trials (RCTs) were 
excluded from the review. Selection of studies was independently 
performed by two reviewers (TC and MM). Where full-text 
manuscripts were not accessible, the corresponding authors were 
contacted. If there was no reply or the full text was not available, 
the study was excluded from this review. Following this process 
(and after a 1-month wait), two studies were excluded from the 
review as only abstracts of these studies have been published.35 36 
Two eligible studies37 38 not published in the English language 
were professionally translated into English by bilingual members 
of the Cochrane collaboration.
Data extraction
Data were independently extracted by two reviewers (TC and 
MM) using the Cochrane data extraction form for RCT inter-
vention reviews (http:// training. cochrane. org/ resource/ data- 
collection- forms- intervention- reviews). Any discrepancies in this 
process were resolved by discussion between the two reviewers, 
followed by reassessment of the data. A system to resolve any 
disagreements was established a priori via discussion with a 
third reviewer (JL), but no such discrepancies occurred. Data 
table 1 Search strategy for the review
sources, searches and search terms
total yield/hits (number of 
new/relevant records)
PubMed: (subacromial pain syndrome OR shoulder pain OR shoulder impingement syndrome OR subacromial impingement OR subacromial bursitis 
OR burs* OR rotator cuff tendin* OR impingement OR tendin* OR tendon OR subacromial OR shoulder) AND (Injection therapy OR injectio*) AND 
(Steroid OR corticosteroid) AND (local anaesthetic OR anaesthetic OR anesthetic) AND (pain OR function)
286 (286)
The Cochrane Library: browsed by topic – musculoskeletal, search narrowed-shoulder, search narrowed-injection 8 (0)
EMBASE: (subacromial pain syndrome OR shoulder pain OR shoulder impingement syndrome OR subacromial impingement OR subacromial bursitis 
OR burs* OR rotator cuff tendin* OR impingement OR tendin* OR tendon OR subacromial OR shoulder) AND (Injection therapy OR injectio*) AND 
(Steroid OR corticosteroid) AND (local anaesthetic OR anaesthetic OR anesthetic) AND (pain OR function)
236 (0)
PEDro: ‘shoulder pain AND injection’,
‘shoulder AND steroid’
80 (0)
34 (0)
CINAHL plus: (subacromial pain syndrome OR shoulder pain OR shoulder impingement syndrome OR subacromial impingement OR subacromial 
bursitis OR burs* OR rotator cuff tendin* OR impingement OR tendin* OR tendon OR subacromial OR shoulder) AND (Injection therapy OR 
injectio*) AND (Steroid OR corticosteroid) AND (local anaesthetic OR anaesthetic OR anesthetic) AND (pain OR function)
58 (0)
Hand searches of relevant reference lists 5 (1)
Total: 287
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extraction for the two non-English studies were performed by 
the bilingual members of the Cochrane collaboration.
risk of bias assessment
Two reviewers independently assessed risk of bias using the 
domain-based Cochrane tool for RCTs (see table 2 and figure 1). 
Trials were evaluated as low risk of bias if all individual criteria 
were low and high if at least one was rated as high (and that 
criterion was deemed by the reviewers to introduce bias).
For further information on this tool, please refer to the 
Cochrane collaboration handbook.39 Exceptions were made if 
a specific criterion was rated as being of high risk of bias but 
this was judged, by the reviewers, not to influence or affect the 
overall risk of bias.
For example, if a clinician performing the injections in 
a study was not blind to the treatment but the patient was 
blinded, and blind outcome assessment was used, then the 
overall risk of bias would be scored as low. Items rated as 
unclear raised the risk of bias.39 An overall risk of bias rating 
for each trial was agreed by two reviews (TC and MM). 
Table 3 details pharmacological information and injection 
method relating to the studies deemed to be at low risk of 
bias. A system to resolve any disagreements was established 
a priori via discussion with a third reviewer (JL). Three such 
disagreements occurred during the risk of bias assessment, 
and consensus was agreed by discussion following review of 
the data. Further discussion with the third reviewer was there-
fore not required.
Data extraction and risk of bias assessment procedures were 
pilot-tested by TC and MM on three similar articles prior to the 
formal review process.40 A Cohen’s kappa coefficient was used 
to assess inter-rater reliability for judgement of high and low 
risk of bias for each criterion. The number of agreements was 
36/39 (92.31%) with a Kappa score of 0.836 and thus the level 
of agreement was considered strong.41
Data syntheses
The studies included in our review used different medications, 
doses and outcome measures (see online supplementary table 
1). Due to these confounding variables, a decision not to pool 
data to perform a meta-analysis was reached. Instead, we used 
a best evidence synthesis to synthesise the results following data 
extraction and assessment of risk of bias. Textual descriptions of 
studies were written to aid the synthesis of findings, and tables 
were used to present study characteristics, data extraction and 
risk of bias assessments. Studies were grouped in accordance 
with their level of risk of bias in order to identify those assessed 
as having the highest level of internal validity.
The best evidence synthesis was based on the quality of the 
studies reviewed42: 
 ► Strong evidence: provided by generally consistent findings 
in multiple high quality RCTs.
 ► Moderate evidence: provided by generally consistent find-
ings in one high-quality RCT plus one or more low-quality 
RCTs, or by generally consistent findings in multiple low 
quality RCTs.
 ► Limited or conflicting evidence: only one RCT (either high 
or low quality) or inconsistent findings in multiple RCTs.
 ► No evidence: no RCTs.
To guide clinical recommendations, studies were combined in 
relation to their outcome timescales34 and whether their results 
favoured CS, local anaesthetic or neither injection type.
rEsults
The electronic database search, performed on 8 June 2017, iden-
tified 286 potentially eligible articles. Hand searches of relevant 
reference lists identified one further article, making a total of 
287 potentially eligible articles. Ultimately, 13 full-text studies 
were included in this systematic review, and seven studies were 
excluded.35 36 43–47 Figure 2 details the PRISMA flow chart.
short-term comparisons (0–12 weeks)
Twelve studies assessed short-term (0–12 weeks) outcomes of 
injection therapy for RCRSP. Five of the 12 studies, four of 
high risk of bias38 48–50 and one of low risk of bias,51 reported 
in favour of CS injections for a range of different outcome 
measures (table 3).
Three further studies, one of high risk of bias52 and two of low 
risk of bias,53 54 reported improvements in the first 4–6 weeks 
in favour of CS but reported no significant difference between 
groups at 12 weeks. The remaining four studies, three of high 
risk of bias37 55 56 and one of low risk of bias,14 reported no 
significant difference in short-term outcomes between the two 
types of injection therapy at any time point.
In summary, three trials51 53 54 (n=417) of low risk of bias 
favoured CS injections for the first 4–8 weeks post-injection, 
and one trial14 of low risk of bias (n=48) found no difference 
between the two types of injection.
Midterm comparisons (13–26 weeks)
In the midterm, two studies50 57 (both of high risk of bias) 
reported a significant difference in outcome favouring CS injec-
tion. One study37 (of high risk of bias) reported a significant 
difference in favour of local anaesthetic injection for pain relief. 
The remaining two studies,14 53 both of low risk of bias and 
including 217 participants, reported that there was no significant 
difference in midterm outcomes between the two types of injec-
tion therapy. Penning et al53 mixed anaesthetic (lidocaine 1%) 
with sodium chloride (0.9%), and the effect of sodium chloride 
may have been a confounding influence. Of note, Penning et al53 
reported that this preparation (lidocaine and sodium chloride), 
designated as the placebo group in this trial, had the best results 
at 26 weeks with respect to reduction in pain and improvement 
in functional mobility.
long-term comparisons (≥1 year)
This review identified only two studies with long-term outcome 
measures of at least 1 year. In summary, in the long term, there 
is evidence from only one study38 (high risk of bias) favouring 
CS injections, and one study54 (low risk of bias, n=179) 
suggesting no significant difference between injection groups.
best evidence synthesis
Using the rating system described in our methods section42 and 
taking into account the results from all 13 studies (both of low 
and high risk of bias) to provide a best evidence synthesis, we 
summarise the following results:
 ► There is strong evidence (from eight trials, three of low risk 
of bias) to suggest a significant benefit of CS injections over 
anaesthetic-only injections for the first 4–8 weeks.
 ► There is strong evidence (from seven trials, three of low risk 
of bias) to suggest that at 12 weeks there is no significant 
difference in outcome between injection types.
 ► There is strong evidence (from two trials of low risk of bias) 
to suggest that there is no significant difference in outcome 
between injection types in the midterm (26 weeks).
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 ► There is limited evidence (from one trial of low risk of bias) 
to suggest that there is no significant difference between 
injection types in the long term (1 year or longer).
In summary, CS injections may have better short-term results 
than anaesthetic-only injections in the first 8 weeks. There does 
not appear to be any convincing evidence from the studies of low 
or high risk of bias that CS injections confer additional benefit 
over anaesthetic-only injections after this time point.
DIscussIOn
The studies evaluated as being at low risk of bias in this review 
have indicated that there may be a temporary initial benefit 
(4–8 weeks) of administering CS in comparison with anaesthetic 
injections for the treatment of RCRSP. There does not appear 
to be any evidence that CS injections confer any additional 
benefit after this time point. We are unable therefore to estab-
lish whether CS medications only afford a therapeutic advantage 
for 4–8 weeks and no added benefit thereafter, or whether they 
provide an initial benefit after which time both medications are 
of equal value.
The certainty of any conclusions reached is challenged by 
the choice, appropriateness and lack of consistency of outcome 
measures used for the patient populations within the individual 
studies. Due to variation in study design and inconsistent use of 
primary outcome measures, we did not pool data.
Although our study differs in its primary objectives and meth-
odology, our findings are similar to those reported in a recent 
review.23 The authors of this recent review did not identify any 
additional evidence that was not included in our review that 
may have influenced our findings. The continued use of CS 
is suggested by the authors to be attributable to ‘habit, to the 
underappreciation of the placebo effect, to satisfy patient desire 
for a physical intervention, or for simple remuneration’.
The majority of the included studies did not perform injection 
therapy in isolation. Although use of concurrent therapy (exer-
cise, analgesics and NSAIDs) was varied, it was balanced within 
each individual trial. There is no definitive way of determining 
the impact of concurrent therapy in addition to the administered 
injections on the reported outcomes. Because of this uncertainty, 
the influence of an independent injection or an injection in 
conjunction with other therapy requires further investigation.
The majority of the investigations included in this review 
described the administration of local anaesthetic injections as a 
placebo procedure, assuming that local anaesthetic injections in 
the subacromial space are inert and do not provide any ther-
apeutic benefit. However, recent evidence suggests that local 
anaesthetics such as lidocaine and bupivaCompleted caine may 
have an effect of reducing tenocyte numbers17 58 and altering 
collagen organisation in tendons.59 Increased cellularity has been 
associated with tendinopathy60 61 and, if elevated, reducing teno-
cyte numbers may be a possible mechanism by which injection 
therapy may contribute to the restoration of tendon homeo-
stasis.6 The manner by which injections may improve symp-
toms remains elusive, and in addition to reducing inflammation, 
restoring tissue homeostasis, reducing the threat of pain and 
placebo,6 it has also been suggested that the therapeutic effect 
of subacromial injections may be the effect of distension of the 
subacromial space.14 Due to these possible chemical, biological 
and physical effects, the assumption that local anaesthetic injec-
tions are a true placebo is challenged and suggests their use may 
provide a therapeutic effect. However, this needs to be balanced 
by a potential deleterious effect.59 Further research is required 
to determine the benefits of the medicines used in these studies 
compared with other medicines, other interventions, natural 
history and a validated placebo. The physiological effects of 
these interventions on the local tissues needs also to be further 
investigated.
Implications for practice
There is a paucity of data quantifying the number of CS injec-
tions performed annually in the UK. Limited evidence from one 
outpatient survey (n=2000) suggested the shoulder was the most 
common anatomical site of musculoskeletal injection, accounting 
for over a third of all injections. Seventy-two per cent of injec-
tions for the shoulder were for the stated treatment of subacro-
mial bursitis (RCRSP).62 Recent United Kingdom National 
Health Service figures reveal that almost 800 000 prescriptions 
of injectable CSs are dispensed nationally within primary care per 
year.63 The average cost of each prescription of CS is estimated 
at £5.16 p, totalling a yearly national cost of over £4 000 000. 
The average cost of a standard dose of local anaesthetic (5 mL of 
1% lidocaine) is £0.24 p.64 We believe it is safe to assume that, 
while exact figures for patients with RCRSP are unknown, the 
cost of CS injections for this patient group is sizeable and, if local 
anaesthetics prove safe and effective in future research, signifi-
cant cost savings could be achieved. Lidocaine-only injections 
Figure 1 Risk of bias graph (frequency (%) of scores per item).
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would be over 20 times less expensive than the average cost of 
CS medication.
Clinically, in addition to cost, is the growing concern regarding 
the negative effects of CS on tendon tissue.26 27 65 It has also been 
suggested that the use of CS injections may detrimentally impact 
the course of lateral epicondyalgia.66 This review has highlighted 
a lack of evidence to support the use of CS injections over local 
anaesthetic injections for the treatment of RCRSP after an 8-week 
period, which raises important issues for clinicians. Should clini-
cians avoid injections entirely? Should clinicians consider local 
anaesthetic injections for patients with RCRSP as the first choice 
of management, and only provide CS injections to those who 
do not respond to local anaesthetic? Additionally, potentially, 
the risks of both CS and anaesthetic-only injection outweigh the 
benefits, as both pharmaceutical products may damage tendon 
tissue. Future research is needed that compares injections of CS, 
local anaesthetic, saline injections, needle only (for the mechan-
ical effect), other products (eg, hyaluronate sodium) an advice-
only group, true placebo and a control group (to map natural 
history). In addition, uncertainty persists over the benefit of 
image-guided versus landmark-guided injection therapy for the 
treatment of RCRSP32 67 and whether the procedure should be 
performed locally or systemically.33
In an investigation of local (CS  to the subacromial bursa and 
local anaesthetic to the gluteal region) versus systemic (CS to the 
gluteal region and local anaesthetic to the subacromial bursa) for 
RCRSP, Ekberg et al33 concluded that as both groups improved, 
both local and systemic injections of CS were equally effective. 
Although this may support a systemic effect of CS, these find-
ings may be confounded for a number of reasons. This review 
suggests that CS injections may confer clinical benefit in the 
first 8 weeks, but beyond this time point both types of injec-
tions and anaesthetic injections appear to be equally effective. 
Therefore, the conclusion that local and systemic CS injections 
are equally effective33 needs to be considered cautiously as the 
benefit reported in this study may have been due to the adminis-
tration of CS and local anaesthetic injections to the subacromial 
bursa. In addition, as there was no control group, the reported 
findings33 may have mapped natural improvement or possibly an 
equivalent placebo response in both groups.
The findings of this review suggest that, in the treatment of 
RCRSP, CS injections may have a more beneficial effect than 
Figure 2 PRISMA flow chart of study selection process. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, 
randomised controlled trials. 
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how might it impact on clinical practice in the future?
 ► Both corticosteroid and anaesthetic-only injections may have 
short-term benefit for people considering injection therapy for 
rotator cuff-related shoulder pain.
 ► Corticosteroid injections may have a superior short-term 
therapeutic effect compared with anaesthetic-only injections, 
but not beyond that time point.
 ► The medium-term and long-term effects of corticosteroid and 
anaesthetic injections are equivocal.
review
anaesthetic injections alone in the short term (up to 8 weeks). 
However, the size of this effect is uncertain and beyond this 
time point, the two medicines appear to have a comparable 
effect. The combination of anaesthetics and sodium chloride 
may be associated with better outcome at 26 weeks.53 Anaes-
thetic alone may also have a positive effect in the short term. 
The uncertainty implies that it is not yet possible to guide 
clinicians on particular circumstances where (1) there is a 
definitive role for injection therapy for RCRSP and (2) when 
CS or anaesthetics may be equally responsive or one may be 
more beneficial than the other. Equally important is that both 
medicines may have a detrimental effect on rotator cuff tissue. 
Shared decision making empowers people seeking healthcare 
to voice their opinions and thoughts. The findings of this 
review may be used to help inform people of the risks and 
benefits of their choices.
lIMItAtIOns
There is debate regarding how to assess risk of bias and method-
ological quality in clinical trials.68
The variety of tools available, covering differing items/
domains, suggest a lack of agreement regarding their relevance.69 
The Cochrane risk of bias tool was used in this review. Although 
widely used, this tool does have some acknowledged challenges; 
these include modest inter-rater agreement and how to deal with 
the risk of bias associated with funding/conflicts of interest.70 In 
this review, inter-rater agreement was strong with both reviewers 
making similar judgements regarding the importance of poten-
tial sources of bias (92.31%, Kappa score of 0.836), and conflict 
of interest data are presented (table 2). The assessment of risk 
of bias in this review was influenced by the amount of incom-
plete or missing information in included studies70 (table 2). This 
contributed to studies being rated as being at high risk of bias 
and, as the majority of studies were assessed as being at poten-
tially high risk of bias, this limited the extent to which the objec-
tive of this review could be achieved.
Although we performed a thorough search of published liter-
ature, we did not perform a search of sources of grey literature 
such as conference papers or government reports. As such, we 
acknowledge this as a potential source of publication bias within 
our literature search.
cOnclusIOns
CS injections may have a short-term benefit (up to 8 weeks) 
over local anaesthetic injections alone in the management of 
RCRSP. However, the certainty of this conclusion is challenged 
due to variations in outcome measures and study design. Beyond 
8 weeks, there was no evidence to suggest a benefit of CS over 
local anaesthetics.
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